Results 191 to 200 of about 765,793 (291)

BCMA CAR T for AL Amyloidosis After Plasmacytic Relapse of Lymphoplasmacytic Lymphoma. [PDF]

open access: yesEJHaem
Al Haddad N   +5 more
europepmc   +1 more source

Placental Site Trophoblastic Tumor Acquires Immune Functions by Incorporating Host Maternal Genes

open access: yesAdvanced Science, Volume 13, Issue 50, 7 September 2026.
PSTT cells, through cell fusion with B cells, incorporate abundant non‐inherited maternal genes that are detectable by DNIMA. These hybrid cells acquire immunotherapy‐resistant genetic changes and increase the expression of B cell‐derived immune‐related molecules such as Ig, HLA, LILRB, SIGLEC10, and so on, creating an immunotolerant environment around
Kyosuke Kagami   +15 more
wiley   +1 more source

Single‐Cell Level Characterization of B Cell Depletion and Repopulation Following Rituximab in Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, Volume 78, Issue 9, Page 1907-1919, September 2026.
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang   +9 more
wiley   +1 more source

Comprehensive Peptide Profiling Reveals the Influence of Streptococcus Thermophilus, Lactobacillus Delbrueckii Subsp. bulgaricus, and Endogenous Milk Proteases on the Hydrolysis of Milk Proteins During Early‐Stage Lactic Acid Fermentation

open access: yesChemFoodChem, Volume 2, Issue 3, September 2026.
Untargeted peptide profiling investigates how S. thermophilus, Lb. bulgaricus, and endogenous milk enzymes impact proteolysis during early‐stage milk fermentation. ≥ 3000 identified peptides show the strongest influence of LB on the peptide profile and number of bioactive peptides. Shorter peptides are mostly formed by LB and hydrolyzed by ST.
Eva Beck   +6 more
wiley   +1 more source

Recent Advancements in Drug Delivery Across the Blood–Brain Barrier in Amyotrophic Lateral Sclerosis (ALS)

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 9, September 2026.
Progressive BBB/BSCB dysfunction is increasingly recognized as both a pathological feature and a therapeutic barrier in ALS. Novel delivery technologies and barrier‐restoration strategies may enhance CNS drug exposure, improve the efficacy of disease‐modifying therapies, and advance ALS treatment. ABSTRACT Background Amyotrophic lateral sclerosis (ALS)
Nitesh Sanghai   +9 more
wiley   +1 more source

CNS Involvement of Multiple Myeloma-A Case Series and Narrative Literature Review. [PDF]

open access: yesJ Clin Med
Andrunache A   +10 more
europepmc   +1 more source

Exercise‐specific plasma proteomic signatures in racehorses: Candidates for training adaptation and peak load monitoring

open access: yesEquine Veterinary Journal, Volume 58, Issue 5, Page 1396-1412, September 2026.
Abstract Background Racehorses undergo profound physiological changes with training and competition, but current biomarkers inadequately capture the complex molecular dynamics of exercise. This study aimed to identify novel plasma biomarkers of training adaptation and peak load using high‐throughput proteomics.
Jowita Grzędzicka   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy